Syn­er­gy out­lines up­beat PhI­II da­ta; Blue­bird and Blue­print rais­ing $375M

Syn­er­gy Phar­ma­ceu­ti­cals $SGYP is fol­low­ing up on the late-stage suc­cess of its lead drug ple­ca­natide for chron­ic id­io­path­ic con­sti­pa­tion with a new batch of up­beat Phase III da­ta cen­tered on ir­ri­ta­ble bow­el syn­drome with con­sti­pa­tion. The study was con­duct­ed among 1,135 pa­tients and the biotech says it will now fol­low up with a new ap­pli­ca­tion in Q1 2017. Syn­er­gy is al­ready look­ing at a PDU­FA date of Jan­u­ary 29 for its first in­di­ca­tion. The com­pa­ny’s shares spiked 6% on the news.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.